Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease

• Published in: Medicine (Baltimore) Vol. 94; no. 33; p. e1161
• Main Authors: Costa, Leandro M.A., Rezende, Paulo C., Garcia, Rosa M.R., Uchida, Augusto H., Seguro, Luis Fernando B.C., Scudeler, Thiago L., Bocchi, Edimar A., Krieger, Jose E., Hueb, Whady, Ramires, José Antonio F., Filho, Roberto Kalil
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc. All rights reserved 01.08.2015; Wolters Kluwer Health
• Subjects: Aged; Coronary Artery Disease - diagnosis; Coronary Artery Disease - physiopathology; Coronary Artery Disease - therapy; Drug Monitoring - methods; Electrocardiography; Exercise Test - methods; Female; Humans; Ischemic Preconditioning - methods; Male; Middle Aged; Observational Study; Outcome Assessment, Health Care; Patient Acuity; Prospective Studies; Trimetazidine - pharmacology; Vasodilator Agents - pharmacology
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000001161

Ischemic preconditioning (IP) is a powerful cardioprotective cellular mechanism that has been related to the "warm-up phenomenon" or "walk-through" angina, and has been documented through the use of sequential exercise tests (ETs). It is known that several drugs, for example, cromokalim, pinacidil, adenosine, and nicorandil, can interfere with the cellular pathways of IP. The purpose of this article is to report the effect of the anti-ischemic agent trimetazidine (TMZ) on IP in symptomatic coronary artery disease (CAD) patients.We conducted a prospective study evaluating IP by the analysis of ischemic parameters in 2 sequential ETs. In phase I, without TMZ, patients underwent ET1 and ET2 with a 30-minute interval between them. In phase II, after 1 week of TMZ 35 mg twice daily, all patients underwent 2 consecutive ETs (ET3 and ET4). IP was considered present when the time to 1.0-mm segment ST on electrocardiogram deviation (T-1.0 mm) and rate pressure product (RPP) were greater in the second of 2 tests. The improvement in T-1.0 mm and RPP were compared in the 2 phases: without TMZ and after 1-week TMZ to assess the action of such drug in myocardial protective mechanisms. ETs were analyzed by 2 independent cardiologists.From 135 CAD patients screened, 96 met inclusion criteria and 62 completed the study protocol. Forty patients manifested IP by demonstrating an improvement in T-1.0 mm in ET2 compared with ET1, without the use of any drugs (phase I). In phase II, after 1-week TMZ, 26 patients (65%) did not show any incremental result in ischemic parameters in ET4 compared with ET3. Furthermore, of these patients, 8 (20%) had IP blockage.In this study, TMZ did not add any benefit to IP in patients with stable symptomatic CAD.